ARKG - ETF AI Analysis
Top Page
ARK Genomic Revolution ETF (ARKG)
Rating:54Neutral
Price Target:―
Positive Factors
Strong Recent Fund Performance
The ETF has shown strong gains so far this year and over the last few months, indicating solid recent momentum.
Leading Genomics Stocks Driving Returns
Several of the largest holdings, such as 10x Genomics and Twist Bioscience, have delivered strong year-to-date performance, helping lift the fund.
Focused Exposure to Innovative Health Care
The fund is heavily invested in health care and genomics companies, giving investors targeted exposure to a fast-evolving area of the market.
Negative Factors
High Concentration in Top Holdings
A small number of stocks make up a large share of the portfolio, which increases the impact that any one company’s performance can have on the ETF.
Mixed Performance Among Key Positions
Some important holdings, including Tempus AI and Crispr Therapeutics, have shown weak year-to-date results, which can drag on overall returns.
Higher Expense Ratio
The ETF charges a relatively high fee, which means more of the fund’s returns are used to cover costs instead of going to investors.
ARKG vs. SPDR S&P 500 ETF (SPY)
AUM1.56B
RegionGlobal
Expense Ratio0.75%
Beta1.68
IssuerARK
Inception DateOct 31, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,706,254
30 Day Avg. Volume3,285,327
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
51.88Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ARKG Summary
ARK Genomic Revolution ETF (ARKG) is a fund that focuses on companies working in genetics and DNA technology, mainly in the U.S. It doesn’t track a traditional index, but instead follows the theme of genomic innovation, including areas like gene editing, DNA testing, and advanced medical research. Well-known holdings include Eli Lilly and Illumina. Someone might invest in ARKG for potential long-term growth from breakthroughs in healthcare and biotechnology, while also getting diversification across many genomic companies. However, this ETF is heavily concentrated in high-risk biotech stocks, so its price can be very volatile and may swing sharply up or down.
How much will it cost me?The ARK Genomic Revolution ETF (ARKG) has an expense ratio of 0.75%, which means you’ll pay $7.50 per year for every $1,000 invested. This is higher than average because the fund is actively managed, allowing it to focus on innovative companies in the fast-evolving genomics sector.
What would affect this ETF?The ARK Genomic Revolution ETF (ARKG) could benefit from continued advancements in genomic technologies like CRISPR and bioinformatics, as well as increased global investment in healthcare innovation. However, it may face challenges from regulatory hurdles in biotechnology, potential economic downturns affecting funding for research, and competition within the healthcare sector. Its global exposure and focus on cutting-edge companies provide growth potential, but also come with risks tied to market volatility and the success of its top holdings.
ARKG Top 10 Holdings
ARKG is leaning heavily into cutting-edge health care, with nearly all its firepower aimed at genomics and precision medicine names around the globe. 10x Genomics has been a key engine for the fund, rising on strong momentum, while Illumina and Natera are also pulling their weight with steady gains. On the flip side, newer or more speculative players like Tempus AI and Crispr Therapeutics are losing steam, acting as a drag. Eli Lilly provides a steadier big-pharma anchor, but this ETF still lives and dies by high-growth, high-volatility biotech stories.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| 10x Genomics | 9.41% | $143.73M | $5.87B | 227.92% | 60 Neutral | |
| Twist Bioscience | 7.80% | $119.12M | $5.62B | 150.82% | 43 Neutral | |
| Tempus AI, Inc. Class A | 6.53% | $99.80M | $7.69B | -33.80% | 52 Neutral | |
| Crispr Therapeutics AG | 6.24% | $95.27M | $4.49B | -28.13% | 40 Underperform | |
| Personalis | 5.21% | $79.62M | $1.26B | 81.51% | 49 Neutral | |
| AbSci | 5.11% | $78.07M | $1.28B | 161.59% | 49 Neutral | |
| Eli Lilly & Co | 4.99% | $76.23M | $1.13T | 47.17% | 72 Outperform | |
| Illumina | 4.59% | $70.09M | $29.37B | 77.58% | 71 Outperform | |
| Guardant Health | 4.41% | $67.41M | $19.54B | 231.67% | 61 Neutral | |
| Natera | 4.13% | $63.15M | $37.52B | 88.62% | 73 Outperform |
ARKG Technical Analysis
Neutral
―
Price Trends
36.36
Positive
32.37
Positive
31.28
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ARKG, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 40.99, equal to the 50-day MA of 36.36, and equal to the 200-day MA of 31.28, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARKG.
ARKG Peer Comparison
Comparison Results
Performance Comparison
ARKG
ARK Genomic Revolution ETF
37.79
12.11
47.16%
ARKK
Ark Innovation Etf
―
―
―
FWD
AB Disruptors ETF
―
―
―
ARKQ
ARK Autonomous Technology & Robotics ETF
―
―
―
CHAT
Roundhill Generative AI & Technology ETF
―
―
―
SQS
Sapient Quality Select ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents